Watanabe Hospital, Ehime, Japan.
Department of Medical Pharmacology, Tokushima University Graduate School, Tokushima, Japan.
J Med Invest. 2024;71(1.2):121-128. doi: 10.2152/jmi.71.121.
Partially hydrolyzed guar gum (PHGG) is a soluble dietary fiber;in addition to improving bowel movements, it maintains intestinal health by producing short-chain fatty acids. However, majority of clinical studies on PHGG have been concluded within a month and excluded usual drug therapy. Hence, this study aimed to determine the effects of long-term consumption of PHGG, in combination with drug therapy, on gut bacteria ratios, laboratory values for inflammatory response, and fecal characteristics.
The study was performed in patients with irritable bowel syndrome (IBS), Crohn's disease (CD), and ulcerative colitis (UC), by the administration of PHGG for six months while they continued their usual treatment. PHGG treatment caused significant changes in patients with IBS, including an increase in the abundance of short-chain fatty acid-producing bacteria, a significant decrease in Bacteroides abundance, and normalization of the Bristol scale of stool. In patients with UC, non-significant normalization of soft stools and decrease in fecal calprotectin were observed. Adverse events were not observed in any of the groups.
Thus, it would be beneficial to include PHGG in the usual drug therapies of patients with IBS. J. Med. Invest. 71 : 121-128, February, 2024.
部分水解瓜尔胶(PHGG)是一种可溶性膳食纤维;除了改善肠道运动外,它还通过产生短链脂肪酸来维持肠道健康。然而,大多数关于 PHGG 的临床研究都在一个月内完成,并排除了常规药物治疗。因此,本研究旨在确定长期(六个月)联合药物治疗 PHGG 对肠道细菌比例、炎症反应的实验室值和粪便特征的影响。
该研究在肠易激综合征(IBS)、克罗恩病(CD)和溃疡性结肠炎(UC)患者中进行,在继续常规治疗的同时给予 PHGG 治疗六个月。PHGG 治疗导致 IBS 患者的显著变化,包括产短链脂肪酸细菌丰度增加、拟杆菌丰度显著降低以及粪便布里斯托分类法正常化。在 UC 患者中,观察到软便非显著正常化和粪便钙卫蛋白减少。各组均未观察到不良事件。
因此,在 IBS 患者的常规药物治疗中加入 PHGG 将是有益的。医学研究杂志 71:121-128,2024 年 2 月。